Alkermes gets FDA orphan tag in mucosal melanoma

 

• Alkermes (NASDAQ:ALKS) receives FDA orphan designation for its fusion protein comprised of a circularly-permuted interleukin-2 (IL-2) with the extracellular domain of IL-2 receptor alpha in the treatment of mucosal melanoma.
• Among the benefits of Orphan Drug status in the U.S. is a seven-year period of market exclusivity for the indication, if approved.

https://newsfilter.io/a/3f859450393f13e8e7b46e33a58b945b